IRIDEX’ Micropulse technology safe, durable for treating glaucoma

by The Medical News • 2014/05/22 • 0 Comments

IRIDEX Corporation (Nasdaq: IRIX) today announced that data from a one-year, multi-center study demonstrates the safety and durability of its proprietary MicroPulse technology as a treatment for glaucoma.

← Iridex reports 16% revenue increase in 2014

Hydrophilic acrylic IOL shows high long-term safety profile for eyes with uveitis →

Post navigation